PDS Biotech has been granted Fast Track designation for PDS0101 in combination with KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer FLORHAM PARK, N.J., June 02, 2022 — PDS Biotechnology […]
Strengthens Patent Portfolio Protecting Horsepox-Based Live Virus Vaccines TNX-1840 and TNX-1850 are Potential RPV Vaccines Designed to Protect Against COVID-19 Confirms Leadership Position in Synthetic Biology Statutory Term of New Patent Expected to Provide Exclusivity […]
NEXT SUPER STOCK AI/ML Innovation (OTC: AIMLF) (CSE: AIML). Does this sub-$10 million market cap stock hold the key patents to the $15 Billion Health Monitoring Wearables Market? ABOUT THE EVENT NEXT SUPER STOCK Live! […]
Vancouver, British Columbia–( May 12, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory […]
– Enrollment Stopped Early for Efficacy – EXTON, Pa., May 17, 2022 — Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (NASDAQ: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, […]
NEW YORK, May 12, 2022 — SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Department of Defense (DoD) awarded a contract to SIGA […]
Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period Statistically significant reductions in the biomarkers Aα-val360 and desmosine […]
Phase 2A Microdose Clinical Study Capsules to be Manufactured VANCOUVER, BC, May 4, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics […]
Selection of lead candidate from initial short-list of 6 DMT-analogues Lead candidate displays superior potency in two in vitro bioassays on two relevant human cell types In vitro safety and biocompatibility testing using drug-loaded medical […]
Databank to focus on mRNA neuroinflammatory markers and serotonin neuro-transmitters VANCOUVER, BC, April 28, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics […]
GeoVax’s Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26, 2022 (GLOBE NEWSWIRE) — GeoVax Labs, Inc. (NASDAQ: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases […]
Provisional patent filed (April 14, 2022) to support use of PD-001 plus cabazitaxel for primary, metastatic and chemotherapy-resistant prostate cancer Final study results show that oral cepharanthine (PD-001) plus cabazitaxel combination therapy significantly reduced tumor […]
29% increase in Twirla cycles27% increase in total prescriptions (TRx) of Twirla PRINCETON, N.J., April 14, 2022– Agile Therapeutics, Inc. (NASDAQ: AGRX), a women’s healthcare company, today announced Twirla prescription data for the first quarter […]
atai Life Sciences N.V. (NASDAQ: ATAI) Q4 2021 Earnings Highlights CEO Florian Brand: “…2021 was a truly transformative year for atai. We made important progress across our programs, expanded our diverse pipeline with multiple shots […]
— Independent Data Monitoring Committee Unanimously Recommends that Phase 3 Clinical Trial for Sabizabulin for Treatment of Hospitalized COVID-19 Patients at High Risk for ARDS Be Stopped Early Due to Overwhelming Evidence of Efficacy — […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
